Cardiovascular organ damage in type 2 diabetes mellitus: the role of lipids and inflammation.


Journal

Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637

Informations de publication

Date de publication:
10 05 2019
Historique:
received: 25 01 2019
accepted: 02 05 2019
entrez: 12 5 2019
pubmed: 12 5 2019
medline: 31 12 2019
Statut: epublish

Résumé

The relationship between dyslipidemia, inflammation and CV organ damage in type 2 diabetes mellitus (T2DM) is complex. Insulin resistance and inflammatory cytokines interleukins (ILs) increase plasma triglycerides (TG). ILs also up-regulate expression of matrix-metalloproteinases (MMPs) that, together with TG, decrease high density lipoprotein cholesterol (HDL) levels. High TG, low HDL, increased ILs and MMPs trigger structural and functional changes in different parts of cardiovascular (CV) system. To understand better the role of lipids and inflammation in CV organ damage, the present study investigated the inter-relationships between lipids, ILs and MMPs, as well as the associations of lipids, ILs and MMPs with various CV measures, both in diabetic and non-diabetic population (nonT2DM). In T2DM patients (N = 191) and nonT2DM subjects (N = 94) were assessed carotid intima-media thickness (cIMT) and inter-adventitial diameter (IADiam), carotid wave speed (ccaWS), carotid-femoral pulse wave velocity (cfPWV), left ventricular (LV) mass, LV systolic (s') and early diastolic (e') longitudinal velocities of mitral annulus, together with glycemic control, lipid profile, IL-6, IL-18 and MMP-12. T2DM patients, as compared to nonT2DM subjects, had significantly higher plasma levels of IL-6, IL-18, MMP-12 and lower HDL (P < 0.05-0.0001). They had also higher cIMT, IADiam, ccaWS, cfPWV and LV mass, and lower e' velocity (P < 0.005-0.0001). Both in T2DM patients and nonT2DM subjects, MMP-12 increased with IL-6 (r = 0.43 and 0.39; P < 0.0001) and IL-18 (r = 0.32 and 0.42; P < 0.0001), and HDL decreased with MMP-12 (r = - 0.29 and - 0.42; P < 0.0001). In both populations, MMP-12 was directly associated with IADiam, ccaWS, cfPWV and LV mass (r = 0.42, 0.32, 0.26 and 0.29; P < 0.0001 in T2DM patients, and r = 0.39, 0.28, 0.32 and 0.27; P < 0.01-0.0001 in nonT2DM subjects). In multivariate analysis, MMP-12 remained independently related to IADiam, ccaWS, cfPWV and LV mass in T2DM patients, and to IADiam only in nonT2DM subjects. This cross-sectional study demonstrated a direct association between ILs and MMP-12, as well as an inverse association between MMP-12 and HDL, both in T2DM patients and in nonT2DM subjects. In T2DM patients, who had higher levels of ILs and MMP-12, the latter was independently related to several structural and functional markers of preclinical CV organ damage.

Sections du résumé

BACKGROUND
The relationship between dyslipidemia, inflammation and CV organ damage in type 2 diabetes mellitus (T2DM) is complex. Insulin resistance and inflammatory cytokines interleukins (ILs) increase plasma triglycerides (TG). ILs also up-regulate expression of matrix-metalloproteinases (MMPs) that, together with TG, decrease high density lipoprotein cholesterol (HDL) levels. High TG, low HDL, increased ILs and MMPs trigger structural and functional changes in different parts of cardiovascular (CV) system. To understand better the role of lipids and inflammation in CV organ damage, the present study investigated the inter-relationships between lipids, ILs and MMPs, as well as the associations of lipids, ILs and MMPs with various CV measures, both in diabetic and non-diabetic population (nonT2DM).
METHODS
In T2DM patients (N = 191) and nonT2DM subjects (N = 94) were assessed carotid intima-media thickness (cIMT) and inter-adventitial diameter (IADiam), carotid wave speed (ccaWS), carotid-femoral pulse wave velocity (cfPWV), left ventricular (LV) mass, LV systolic (s') and early diastolic (e') longitudinal velocities of mitral annulus, together with glycemic control, lipid profile, IL-6, IL-18 and MMP-12.
RESULTS
T2DM patients, as compared to nonT2DM subjects, had significantly higher plasma levels of IL-6, IL-18, MMP-12 and lower HDL (P < 0.05-0.0001). They had also higher cIMT, IADiam, ccaWS, cfPWV and LV mass, and lower e' velocity (P < 0.005-0.0001). Both in T2DM patients and nonT2DM subjects, MMP-12 increased with IL-6 (r = 0.43 and 0.39; P < 0.0001) and IL-18 (r = 0.32 and 0.42; P < 0.0001), and HDL decreased with MMP-12 (r = - 0.29 and - 0.42; P < 0.0001). In both populations, MMP-12 was directly associated with IADiam, ccaWS, cfPWV and LV mass (r = 0.42, 0.32, 0.26 and 0.29; P < 0.0001 in T2DM patients, and r = 0.39, 0.28, 0.32 and 0.27; P < 0.01-0.0001 in nonT2DM subjects). In multivariate analysis, MMP-12 remained independently related to IADiam, ccaWS, cfPWV and LV mass in T2DM patients, and to IADiam only in nonT2DM subjects.
CONCLUSIONS
This cross-sectional study demonstrated a direct association between ILs and MMP-12, as well as an inverse association between MMP-12 and HDL, both in T2DM patients and in nonT2DM subjects. In T2DM patients, who had higher levels of ILs and MMP-12, the latter was independently related to several structural and functional markers of preclinical CV organ damage.

Identifiants

pubmed: 31077210
doi: 10.1186/s12933-019-0865-6
pii: 10.1186/s12933-019-0865-6
pmc: PMC6511166
doi:

Substances chimiques

Biomarkers 0
Inflammation Mediators 0
Interleukins 0
Lipids 0
Matrix Metalloproteinases EC 3.4.24.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

61

Références

Surgery. 2005 Apr;137(4):457-62
pubmed: 15800495
Atherosclerosis. 2014 Jan;232(1):65-71
pubmed: 24401218
J Clin Invest. 2003 Nov;112(9):1419-28
pubmed: 14597767
J Am Soc Echocardiogr. 2019 Feb;32(2):216-232.e2
pubmed: 30717860
J Clin Endocrinol Metab. 2005 Mar;90(3):1495-501
pubmed: 15613416
Atherosclerosis. 2005 Jan;178(1):19-23
pubmed: 15585196
Diabetes Care. 2016 Aug;39 Suppl 2:S244-52
pubmed: 27440839
Heart. 2014 Nov;100(21):1673-80
pubmed: 24860005
Circulation. 1982 Jan;65(1):99-108
pubmed: 7053293
Cardiovasc Diabetol. 2017 May 12;16(1):64
pubmed: 28499385
Diabetes Care. 2018 Oct;41(10):2212-2219
pubmed: 30061319
Immunobiology. 2017 Oct;222(10):937-943
pubmed: 27613200
J Hypertens. 2011 Feb;29(2):319-24
pubmed: 21150641
Diabetes Care. 2009 Nov;32 Suppl 2:S373-7
pubmed: 19875584
Int J Cardiol. 2016 Jul 15;215:364-71
pubmed: 27128563
Atherosclerosis. 2007 Jun;192(2):384-90
pubmed: 16787648
Diabetes Care. 2016 Jan;39 Suppl 1:S13-22
pubmed: 26696675
Ann Med. 2014 Feb;46(1):44-8
pubmed: 24432723
J Hypertens. 2018 Dec;36(12):2362-2368
pubmed: 30044312
Circulation. 2009 May 19;119(19):2578-86
pubmed: 19414640
Endocrinology. 1995 May;136(5):2143-9
pubmed: 7720663
Blood. 1999 Sep 15;94(6):2080-9
pubmed: 10477738
Sci Rep. 2015 Nov 26;5:17189
pubmed: 26608672
Sci Transl Med. 2017 Oct 11;9(411):
pubmed: 29021167
J Biol Chem. 1999 Aug 6;274(32):22627-34
pubmed: 10428843
Biochem Pharmacol. 2008 Jan 15;75(2):346-59
pubmed: 17678629
Angiology. 2005 Mar-Apr;56(2):173-89
pubmed: 15793607
BMC Cardiovasc Disord. 2013 May 03;13:34
pubmed: 23642232
J Hypertens. 2013 Aug;31(8):1584-92
pubmed: 23822928
J Am Coll Cardiol. 1995 Apr;25(5):1056-62
pubmed: 7897116
Cardiovasc Res. 2016 Jun 1;110(3):298-308
pubmed: 27009176
Eur Heart J. 2013 Aug;34(30):2368-80
pubmed: 23186808
Am J Physiol Heart Circ Physiol. 2010 May;298(5):H1608-15
pubmed: 20207811
Circ Cardiovasc Imaging. 2016 Jul;9(7):
pubmed: 27353852
Clin Chem Lab Med. 2001 May;39(5):380-4
pubmed: 11434385
J Clin Invest. 1975 Jul;56(1):56-64
pubmed: 124746
Matrix Biol. 2015 May-Jul;44-46:224-31
pubmed: 25599938
Diabetes Metab J. 2015 Oct;39(5):353-62
pubmed: 26566492
Cardiovasc Ultrasound. 2010 Jul 26;8:29
pubmed: 20659321
Diabetes Care. 2012 Jan;35(1):158-62
pubmed: 22040842
Eur Heart J Cardiovasc Imaging. 2015 Jun;16(6):577-605
pubmed: 25995329
Hypertension. 2005 Apr;45(4):586-91
pubmed: 15738348
Lipids Health Dis. 2016 May 18;15:97
pubmed: 27192979
Lancet. 2010 Jun 26;375(9733):2215-22
pubmed: 20609967
Diabetes Care. 2013 Jan;36(1):166-75
pubmed: 23264288
Dis Markers. 2013;35(4):235-41
pubmed: 24167372
J Vasc Surg. 2007 Apr;45(4):849-57
pubmed: 17398401
Arterioscler Thromb Vasc Biol. 2015 Jul;35(7):1723-31
pubmed: 25953645
Eur Heart J. 2010 Oct;31(19):2338-50
pubmed: 20530030
Hypertension. 2010 Aug;56(2):225-31
pubmed: 20606113

Auteurs

Michaela Kozakova (M)

Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, 56126, Pisa, Italy.

Carmela Morizzo (C)

Department of Surgical, Medical Molecular Pathology and Critical Care Medicine, University of Pisa, Via Savi 10, 56126, Pisa, Italy.

Isabel Goncalves (I)

Department of Clinical Sciences Malmö, Lund University, Jan Waldenströms gata 35, 20502, Malmö, Sweden.

Andrea Natali (A)

Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, 56126, Pisa, Italy.

Jan Nilsson (J)

Department of Clinical Sciences Malmö, Lund University, Jan Waldenströms gata 35, 20502, Malmö, Sweden.

Carlo Palombo (C)

Department of Surgical, Medical Molecular Pathology and Critical Care Medicine, University of Pisa, Via Savi 10, 56126, Pisa, Italy. carlo.palombo@unipi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH